NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP
Press Release
Read More
NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference
Press Release
Read More
NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023
Press Release
Read More
RaDaR® Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery
Press Release
Read More
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Literature
Read More
High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma
Literature
Read More